ChromaDex to Join Virtual Investor Event on August 29, 2024

LOS ANGELES—ChromaDex Corp. (NASDAQ:CDXC), a leader in nicotinamide adenine dinucleotide (NAD+) research, has announced its participation in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series. The live event is scheduled for August 29, 2024, at 2:00 PM EDT, where the company will present its latest investor insights. Stakeholders, investors, and interested individuals are encouraged to register for the event. The presentation will feature key executives, including Rob Fried, Chief Executive Officer; James Lee, Interim Chief Financial Officer; and Wesley Yu, Vice President of Finance. Participants are advised to register in advance, as attendance may be limited. For those unable to attend, a replay of the presentation will be available on ChromaDex’s Investor website following the event. ChromaDex is recognized as the global authority on NAD+ and its implications for healthy aging. NAD+ is a crucial coenzyme present in every human cell, but its levels decline with age and various stressors, contributing to age-related health issues. The company’s flagship product, Tru Niagen®, contains Niagen, the leading NAD+ supplement in the United States, aimed at combating the effects of NAD+ depletion. For further information, interested parties can access the source version of the announcement on Business Wire or contact the company’s investor relations team.